Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HG6G | ISIN: SE0000736415 | Ticker-Symbol: C5G
Frankfurt
06.06.25 | 19:59
1,734 Euro
+17,80 % +0,262
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
OREXO AB Chart 1 Jahr
5-Tage-Chart
OREXO AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,5841,74006.06.

Aktuelle News zur OREXO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoOrexo to present clinical data for OX640 at the EAACI Congress178OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI...
► Artikel lesen
06.05.Orexo Q1 2025 slides: stable revenue growth amid pipeline advancements1
06.05.Orexo AB: Orexo Q1 2025 Interim Report79Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency...
► Artikel lesen
10.04.Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology305The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations...
► Artikel lesen
06.02.Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report84Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of...
► Artikel lesen
10.01.Orexo Announces Positive Data From Clinical Study Of OX640 Evaluating Allergic Reactions1
OREXO Aktie jetzt für 0€ handeln
10.01.Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis391OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical...
► Artikel lesen
18.12.24Abera and Orexo partner for vaccine powder formulations2
17.12.24Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology2
17.12.24Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology452The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical...
► Artikel lesen
02.12.24Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis275Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for...
► Artikel lesen
25.10.24Orexo initiates new study of OX640 in participants with allergic rhinitis310OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery...
► Artikel lesen
24.10.24Orexo Interim Report Q3 2024459UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ -- Q3 2024 highlights › Total net revenues of SEK 136.5 m (156.1) › EBITDA of SEK -0.7 m (-9.5) › Net earnings of SEK -41.9...
► Artikel lesen
04.10.24Orexo's Nomination Committee for the Annual General Meeting 2025318UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises...
► Artikel lesen
03.09.24Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024317UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15th Annual Healthcare Conference...
► Artikel lesen
17.07.24Orexo Q2 2024 Interim Report417UPPSALA, Sweden, July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7)EBITDA of SEK...
► Artikel lesen
16.07.24Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose413UPPSALA, Sweden, July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food...
► Artikel lesen
10.07.24Orexo AB's sustainability work ranked among top 5% by EcoVadis467UPPSALA, Sweden, July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world's most trusted...
► Artikel lesen
08.07.24Orexo: invitation to presentation of the Q2 2024 Interim Report413UPPSALA, Sweden, July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1